May 2026 in “Reviews in Endocrine and Metabolic Disorders” This review explores weight loss interventions during gestation, emphasizing incretin-based therapies' potential to enhance reproductive health and address metabolic changes for better maternal and fetal outcomes.
1 citations
,
September 2025 in “Dermatology and Therapy” This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.
July 2023 in “Journal of Clinical Medicine” This study reviews current treatments for PCOS and evaluates Tirzepatide as a potential option for its management, suggesting possible benefits for those with obesity and metabolic syndrome but not for those of normal weight.
June 2026 in “Dermatology and Therapy” In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.
December 2024 in “Cureus” This case report describes significant symptom improvement and hair regrowth in a man with recalcitrant folliculitis decalvans after starting tirzepatide for weight management, suggesting a potential new therapy avenue.